Comparing cataract surgery with a new corneal transplant technique for patients with cataracts and Fuchs dystrophy
Official title: European Prospective Multicentre Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy (ETCF-trial)
Run by University of Cologne · NCT06425666 · Data updated 2026-11-12
This study is testing whether a new corneal transplant technique combined with cataract surgery can improve vision and quality of life for people with cataracts and Fuchs dystrophy compared to standard cataract surgery alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of Cologne Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Aarhus N, Central Jutland and 3 other locations) |
| Status | Recruiting |
| Started | January 24, 2025 |
| Main results expected | March 2026 |
| Study ends | June 2026 |
| Registry record updated | February 21, 2025 |
| Trial ID | NCT06425666 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with nuclear cataracts and Fuchs Endothelial Corneal Dystrophy.
✕Probably not a fit
Patients with significant ocular or systemic comorbidities affecting vision may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of two surgical approaches for patients suffering from cataracts and Fuchs Endothelial Corneal Dystrophy. Participants will be randomly assigned to either receive standard cataract surgery or a combined procedure that includes cataract surgery and a novel triple-DMEK corneal transplant. The study aims to assess differences in best-corrected visual acuity (BCVA), safety, quality of life, and other visual functions between the two groups. Comprehensive ocular examinations and quality of life questionnaires will be utilized to gather data on patient outcomes.
Why it matters
Potential benefit: If successful, this study could improve visual outcomes and quality of life for patients with cataracts and Fuchs dystrophy.
How similar studies have gone: Other studies have shown promise with similar surgical approaches, but this specific combination is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with FECD and nuclear cataract in study eye 2. Male and female patients ≥18 years of age 3. Subject must be able to understand and read the national language. 4. Written informed consent prior to any study-related procedures 5. Nuclear opalescence (NO) grades 2 and 3 according to the lens opacities classification system III (LOCS III) 6. Krachmer grade (3 \[2-5 mm diameter area with confluent guttae\]; 4 \[ \> 5 mm diameter area with confluent guttae\] without edema identified by slit lamp examination) 7. Central corneal thickness (CCT) measured with Pentacam below 620 µm between 8:00 am and 01:00 pm 8. BCVA logMAR \< 0,7 and \> 0,1 9. No previous cataract surgery or triple-DMEK on the opposite side 10. Pentacam quality specification: "OK" 11. For women below age of 60 negative urine pregnancy test Exclusion Criteria: 1. Patients with ocular and/or systemic comorbidity affecting vision or clinically proven anterior and/or posterior segment disease other than FECD and cataract (exclusion of macular disease or edema by OCT) 2. Iris synechiae, pupil diameter \<6 mm after dilatation, pseudoexfoliation syndrome, subluxated lens, previous history of ocular trauma/surgery or inflammatory disease 3. Subjective diurnal changes in visual acuity with worse visual acuity in the morning 4. Corneal (epithelial) edema visible at slit lamp examination 5. Preoperative anterior chamber depth below 2 mm 6. Participation in other interventional trials parallel or within the last 4 weeks 7. Systemic use of Alpha-1-Adrenozeptor-Antagonists, immunosuppressive therapy or chemotherapy 8. Pregnant women and nursing mothers 9. Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator 10. Legally incapacitated persons 11. Persons held in an institution by legal or official order
Where it's running
-
Klinik für Ophthalmologie des Universitätsklinikums Köln
Cologne, North Rhine-Westphalia, Germany Recruiting -
Department of Ophthalmology, Aarhus University Hospital
Aarhus N, Central Jutland, Denmark Not yet recruiting -
Radboud-Universität Nijmegen
Nijmegen, Gelderland, Netherlands Not yet recruiting -
Instituto de microcirugía ocular; Departamento de Cornea y Cirugia Refractiva
Barcelona, Barcelona, Spain Not yet recruiting
Study contacts
- Principal investigator: Björn Bachmann, Prof. — University Hospital of Cologne
- Study coordinator: Björn Bachmann, Prof.
- Email: bjoern.bachmann@uk-koeln.de
- Phone: 0049-221 478-87476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Feasibility of using a head-mounted spatial display during intraocular surgery
This study tests whether Apple Vision Pro can help surgeons visualize information during cataract and other intraocular surgeries.
-
Lacrifill to Help Prevent Post-Curgery Dry Eye After Cataract Surgery
This study tests Lacrifill to see if it helps prevent dry eye symptoms after unilateral cataract surgery.
-
Shortening waiting time for cataract surgery
This project will try standard operating procedures to see if better coordination between wards and the operating room shortens waiting time for adults having cataract surgery.
-
Visual outcomes after cataract and refractive procedures
This project uses past clinical records to see how adults who had cataract surgery with an intraocular lens or refractive procedures fared in vision and refraction and to compare different IOLs and procedures.
-
Which eye drop—bromfenac, nepafenac, or diclofenac—works best after cataract surgery?
This trial will try three different anti-inflammatory eye drops (bromfenac 0.09%, nepafenac 0.3%, and diclofenac 0.1%) to see which best prevents or treats cystoid macular edema in adults having cataract surgery.
-
Evaluating outcomes of Clareon Vivity lenses in patients with previous vision correction surgery
This study is testing how well Clareon Vivity lenses work for people with age-related cataracts who have previously had vision correction surgery like LASIK or PRK.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.